JP2021519308A5 - - Google Patents
Info
- Publication number
- JP2021519308A5 JP2021519308A5 JP2020551963A JP2020551963A JP2021519308A5 JP 2021519308 A5 JP2021519308 A5 JP 2021519308A5 JP 2020551963 A JP2020551963 A JP 2020551963A JP 2020551963 A JP2020551963 A JP 2020551963A JP 2021519308 A5 JP2021519308 A5 JP 2021519308A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- groups
- cancer
- alkoxy
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650151P | 2018-03-29 | 2018-03-29 | |
| US62/650,151 | 2018-03-29 | ||
| PCT/US2019/024976 WO2019191667A1 (en) | 2018-03-29 | 2019-03-29 | Imidazopiperazine inhibitors of transcription activating proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021519308A JP2021519308A (ja) | 2021-08-10 |
| JP2021519308A5 true JP2021519308A5 (enExample) | 2022-03-30 |
| JP7387627B2 JP7387627B2 (ja) | 2023-11-28 |
Family
ID=68057632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551963A Active JP7387627B2 (ja) | 2018-03-29 | 2019-03-29 | 転写活性化タンパク質のイミダゾピペラジン阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11058688B2 (enExample) |
| EP (1) | EP3773587A4 (enExample) |
| JP (1) | JP7387627B2 (enExample) |
| KR (1) | KR102815607B1 (enExample) |
| CN (1) | CN112165944B (enExample) |
| AU (2) | AU2019245403B2 (enExample) |
| BR (1) | BR112020019824A2 (enExample) |
| CA (1) | CA3095367A1 (enExample) |
| IL (1) | IL277628A (enExample) |
| RU (1) | RU2020131507A (enExample) |
| WO (1) | WO2019191667A1 (enExample) |
| ZA (1) | ZA202006092B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2020131507A (ru) | 2018-03-29 | 2022-05-04 | Боард Оф Реджентс, Де Юниверсити Оф Техас Систем | Имидазопиперазиновые ингибиторы белков-активаторов транскрипции |
| WO2019195846A1 (en) | 2018-04-06 | 2019-10-10 | Board Of Regents, The University Of Texas System | Imidazopiperazinone inhibitors of transcription activating proteins |
| KR102939417B1 (ko) | 2020-04-25 | 2026-03-17 | 파마블럭 사이언시스 (난징), 인코포레이티드 | Cbp/ep 300 억제제 및 이의 용도 |
| EP4221708A4 (en) | 2020-10-02 | 2024-11-06 | Board of Regents, The University of Texas System | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION-ACTIVATING PROTEINS |
| CA3193745A1 (en) * | 2020-10-02 | 2022-04-07 | Kang Le | Imidazopiperazine inhibitors of transcription activating proteins |
| US20240122941A1 (en) * | 2020-12-25 | 2024-04-18 | National Cancer Center | Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer |
| CN121851016A (zh) * | 2021-04-21 | 2026-04-14 | 长春金赛药业有限责任公司 | 含咪唑稠环类衍生物、其制备方法及其在医药上的应用 |
| CN113429427A (zh) * | 2021-07-05 | 2021-09-24 | 湖南南新制药股份有限公司 | 杂环化合物及其制备方法和药物用途 |
| CN115724857B (zh) * | 2021-08-25 | 2024-06-21 | 杭州禹泓医药科技有限公司 | 一种芳杂环类化合物、含其的药物组合物及其应用 |
| CN116410211A (zh) * | 2021-12-29 | 2023-07-11 | 山东新时代药业有限公司 | 一种苯并呋喃类化合物 |
| CN116478130B (zh) * | 2022-01-21 | 2025-05-30 | 深圳默元生物科技有限公司 | N-羟基喹啉甲酰胺化合物及其用途 |
| WO2023235809A1 (en) * | 2022-06-02 | 2023-12-07 | Eli Lilly And Company | Cgas inhibitors |
| WO2025111184A1 (en) | 2023-11-21 | 2025-05-30 | Fmc Corporation | Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1537114T3 (da) | 2002-08-07 | 2006-11-13 | Novartis Ag | Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande |
| US20070004736A1 (en) | 2002-11-22 | 2007-01-04 | Keiji Kubo | Imidazole derivative, process for producing the same, and use |
| MX2008015008A (es) | 2006-05-26 | 2008-12-05 | Novartis Ag | INHIBIDORES DE SINTASA DE ALDOSTERONA Y/O DE 11ß-HIDROXILASA. |
| US7943617B2 (en) * | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
| WO2008078291A1 (en) | 2006-12-22 | 2008-07-03 | Actelion Pharmaceuticals Ltd | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives |
| CN101686989B (zh) | 2007-06-21 | 2016-10-19 | 卡拉治疗学股份有限公司 | 取代的咪唑并杂环 |
| US8859538B2 (en) | 2007-06-21 | 2014-10-14 | Cara Therapeutics, Inc. | Uses of substituted imidazoheterocycles |
| CN101417999A (zh) | 2007-10-25 | 2009-04-29 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| CN101468988A (zh) | 2007-12-26 | 2009-07-01 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| CN102076694A (zh) | 2008-06-25 | 2011-05-25 | 埃科特莱茵药品有限公司 | 5，6，7，8-四氢-咪唑并[1，5-a]吡嗪化合物 |
| PE20120121A1 (es) * | 2008-12-08 | 2012-02-20 | Gilead Connecticut Inc | Derivados de imidazopirazina como inhibidores de syk |
| WO2011092120A1 (en) | 2010-01-29 | 2011-08-04 | Nerviano Medical Sciences S.R.L. | 6,7- dihydroimidazo [1,5-a] pyrazin-8 (5h) - one derivatives as protein kinase modulators |
| CN102372716A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| US9145418B2 (en) | 2011-10-07 | 2015-09-29 | Nerviano Medical Sciences S.R.L. | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors |
| CN103087067A (zh) * | 2012-08-02 | 2013-05-08 | 盛世泰科生物医药技术(苏州)有限公司 | 作为二肽基酶抑制剂的化合物及其组合物，以及它们的用途 |
| US9695176B2 (en) | 2012-10-18 | 2017-07-04 | Bristol-Myers Squibb Company | Substituted imidazo[1,5-a]pyrazines as CGRP receptor antagonists |
| US20160113893A1 (en) * | 2013-06-12 | 2016-04-28 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| WO2014206150A1 (en) * | 2013-06-28 | 2014-12-31 | Abbvie Inc. | Bromodomain inhibitors |
| JP6820254B2 (ja) | 2014-10-10 | 2021-01-27 | ジェネンテック， インコーポレイテッド | 治療用化合物およびその使用 |
| EP3632915A1 (en) | 2014-11-27 | 2020-04-08 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| EP3445750A4 (en) | 2016-04-18 | 2019-11-27 | Celgene Quanticel Research, Inc. | THERAPEUTIC COMPOUNDS |
| JP7014736B2 (ja) | 2016-05-24 | 2022-02-01 | ジェネンテック， インコーポレイテッド | がんの処置のためのピラゾロピリジン誘導体 |
| EP3464270B1 (en) | 2016-05-24 | 2022-02-23 | Genentech, Inc. | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer |
| RU2020131507A (ru) | 2018-03-29 | 2022-05-04 | Боард Оф Реджентс, Де Юниверсити Оф Техас Систем | Имидазопиперазиновые ингибиторы белков-активаторов транскрипции |
| WO2019195846A1 (en) | 2018-04-06 | 2019-10-10 | Board Of Regents, The University Of Texas System | Imidazopiperazinone inhibitors of transcription activating proteins |
-
2019
- 2019-03-29 RU RU2020131507A patent/RU2020131507A/ru unknown
- 2019-03-29 CA CA3095367A patent/CA3095367A1/en active Pending
- 2019-03-29 EP EP19777484.7A patent/EP3773587A4/en active Pending
- 2019-03-29 JP JP2020551963A patent/JP7387627B2/ja active Active
- 2019-03-29 CN CN201980035368.2A patent/CN112165944B/zh active Active
- 2019-03-29 US US16/370,404 patent/US11058688B2/en active Active
- 2019-03-29 KR KR1020207031004A patent/KR102815607B1/ko active Active
- 2019-03-29 AU AU2019245403A patent/AU2019245403B2/en active Active
- 2019-03-29 BR BR112020019824-2A patent/BR112020019824A2/pt not_active Application Discontinuation
- 2019-03-29 WO PCT/US2019/024976 patent/WO2019191667A1/en not_active Ceased
-
2020
- 2020-09-27 IL IL277628A patent/IL277628A/en unknown
- 2020-10-01 ZA ZA2020/06092A patent/ZA202006092B/en unknown
-
2021
- 2021-05-21 US US17/327,217 patent/US12186324B2/en active Active
-
2024
- 2024-11-06 US US18/938,730 patent/US20250127792A1/en active Pending
-
2025
- 2025-04-29 AU AU2025202971A patent/AU2025202971A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519308A5 (enExample) | ||
| JP2015534580A5 (enExample) | ||
| FI3328827T3 (fi) | Glutamiinianalogien aihiolääkkeitä | |
| JP2015534578A5 (enExample) | ||
| RU2020111366A (ru) | Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения | |
| MX2021005214A (es) | Farmacos anti-estrogenicos tetrahidro-1h-pirido [3,4-b] indol. | |
| JP2017510641A5 (enExample) | ||
| JP2017186337A5 (enExample) | ||
| JP2018536624A5 (enExample) | ||
| JP2015534579A5 (enExample) | ||
| RU2014101626A (ru) | Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты | |
| MX338831B (es) | Moduladores selectivos de receptores de androgenos. | |
| WO2009105214A3 (en) | Selective androgen receptor modulators | |
| WO2010118287A8 (en) | Selective androgen receptor modulators | |
| JP2018516966A5 (enExample) | ||
| JP2015527318A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| JP2014055156A5 (enExample) | ||
| JP2019524714A5 (enExample) | ||
| AU2012288626A8 (en) | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as EGFR modulators useful for treating cancer | |
| JP2013523784A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| MY183927A (en) | Pyridinyl and fused pyridinyl triazolone derivatives | |
| JP2024519188A5 (enExample) | ||
| JP2019527239A5 (enExample) |